NCT00727298View on ClinicalTrials.gov

Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)

CompletedOBSERVATIONAL

Enrollment

4,485

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Arthritis, RheumatoidSpondylitis, AnkylosingArthritis, PsoriaticPsoriasisCrohn's Disease

Interventions

BIOLOGICAL

Infliximab

Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.